GPER modulators: Opportunity Nox on the heels of a class Akt
- 1 February 2018
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 176, 73-81
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (CA127731, CA163890, CA194496)
- UNM Comprehensive Cancer Center (P30 CA118100)
This publication has 194 references indexed in Scilit:
- Endometrial CancerObstetrics and Gynecology Clinics of North America, 2012
- Evidence That the G Protein–Coupled Membrane Receptor GPR30 Contributes to the Cardiovascular Actions of EstrogenGender Medicine, 2011
- Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivityThe Journal of Steroid Biochemistry and Molecular Biology, 2011
- The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular functionVascular Pharmacology, 2011
- GPR30 is positioned to mediate estrogen effects on basal forebrain cholinergic neurons and cognitive performanceBrain Research, 2011
- The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancerCurrent Opinion in Pharmacology, 2010
- Mechanisms of estrogen signaling and gene expression via GPR30Molecular and Cellular Endocrinology, 2009
- Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosisJournal of Neuroimmunology, 2009
- Estradiol rescues neurons from global ischemia-induced cell death: Multiple cellular pathways of neuroprotectionSteroids, 2009
- Nox enzymes, ROS, and chronic disease: An example of antagonistic pleiotropyFree Radical Biology and Medicine, 2007